Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | T599K |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | BRAF T599K lies within the protein kinase domain of the Braf protein (UniProt.org). T599K is predicted to lead to a gain of Braf protein function as demonstrated by increased Erk phosphorylation in culture, and is associated with resistance to Raf inhibitors (PMID: 31158244). |
Associated Drug Resistance | Y |
Category Variants Paths |
BRAF mutant BRAF act mut BRAF T599K BRAF mutant BRAF T599X BRAF T599K |
Transcript | NM_004333.6 |
gDNA | chr7:g.140753339G>T |
cDNA | c.1796C>A |
Protein | p.T599K |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001354609.1 | chr7:g.140753339G>T | c.1796C>A | p.T599K | RefSeq | GRCh38/hg38 |
XM_005250045 | chr7:g.140753339G>T | c.1796C>A | p.T599K | RefSeq | GRCh38/hg38 |
NM_001378473.1 | chr7:g.140749326_140749327delCTinsAG | c.1796_1797delCTinsAG | p.T599K | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140753339G>T | c.1796C>A | p.T599K | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140753339G>T | c.1796C>A | p.T599K | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140753339G>T | c.1796C>A | p.T599K | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140753339G>T | c.1796C>A | p.T599K | RefSeq | GRCh38/hg38 |
NM_004333 | chr7:g.140753339G>T | c.1796C>A | p.T599K | RefSeq | GRCh38/hg38 |
NM_001378472.1 | chr7:g.140749326_140749327delCTinsAG | c.1796_1797delCTinsAG | p.T599K | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140753339G>T | c.1796C>A | p.T599K | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03843775 | Phase Ib/II | Binimetinib + Encorafenib | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | Completed | USA | 0 |